• 1. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312
• 2. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 3. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 4. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277
• 5. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Stilbenes Stilbenes
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Stilbenes

Compound Introduction: (5R,6S)-5,6-Diphenylmorpholin-2-one (CAS No. 282735-66-4)

(5R,6S)-5,6-Diphenylmorpholin-2-one (CAS No. 282735-66-4) is a structurally complex organic molecule that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology due to its unique pharmacophoric features. This compound belongs to the morpholine derivative class, characterized by a morpholine ring system substituted with phenyl groups at the 5 and 6 positions, and a carbonyl group at the 2-position. The specific stereochemistry at the 5R and 6S configurations further distinguishes it from other analogs, making it a subject of intense interest for its potential biological activity.

The synthesis of (5R,6S)-5,6-Diphenylmorpholin-2-one involves multi-step organic transformations that require precise control over reaction conditions to achieve high enantiomeric purity. The stereochemistry of the morpholine ring is particularly critical, as it can significantly influence the compound's binding affinity and pharmacological effects. Advanced synthetic methodologies, such as asymmetric catalysis and chiral resolution techniques, have been employed to obtain the desired enantiomerically pure form of this compound. These synthetic strategies not only highlight the synthetic challenge but also underscore the importance of molecular architecture in drug design.

In recent years, (5R,6S)-5,6-Diphenylmorpholin-2-one has been investigated for its potential therapeutic applications in several disease models. Its morpholine core is a common pharmacophore found in various bioactive molecules, suggesting that it may interact with biological targets in a manner similar to known drugs. Preliminary studies have indicated that this compound exhibits promising activity in modulating certain enzymatic pathways and receptor interactions. For instance, research has explored its potential role in inhibiting enzymes involved in inflammation and pain signaling pathways. The phenyl substituents at the 5 and 6 positions are thought to enhance binding affinity by improving hydrophobic interactions with target proteins.

The pharmacokinetic properties of (5R,6S)-5,6-Diphenylmorpholin-2-one are also of considerable interest. Due to its complex structure, understanding how it is metabolized and eliminated by the body is crucial for optimizing its therapeutic index. Computational modeling and experimental techniques such as mass spectrometry have been utilized to study its metabolic pathways. These studies have provided insights into how the compound is processed by enzymes like cytochrome P450 (CYP450), which are pivotal in drug metabolism. This information is essential for predicting potential drug-drug interactions and for designing more effective derivatives.

One of the most exciting aspects of (5R,6S)-5,6-Diphenylmorpholin-2-one is its potential in developing novel therapeutic agents for neurological disorders. The morpholine scaffold has shown promise in modulating neurotransmitter systems, making it a valuable candidate for drugs targeting conditions such as Alzheimer's disease and Parkinson's disease. Recent preclinical studies have demonstrated that derivatives of this compound can cross the blood-brain barrier and exhibit neuroprotective effects. The stereochemistry at the 5R and 6S positions appears to be crucial for these effects, suggesting that enantiopure forms like (5R,6S)-5,6-Diphenylmorpholin-2-one may offer enhanced efficacy with fewer side effects compared to racemic mixtures.

The development of (5R,6S)-5,6-Diphenylmorpholin-2-one also aligns with broader trends in medicinal chemistry towards rational drug design. By leveraging structural biology and computational methods, researchers can predict how modifications to this molecule might improve its potency or selectivity for specific targets. For example, computational docking studies have been used to model how this compound interacts with various protein receptors. These studies not only provide a mechanistic understanding of its action but also guide future modifications aimed at enhancing its therapeutic profile.

Another area where (5R,6S)-5,6-Diphenylmorpholin-2-one shows promise is in oncology research. Certain morpholine derivatives have been identified as inhibitors of kinases involved in cancer cell proliferation. Preliminary experiments suggest that this compound may interfere with signaling pathways critical for tumor growth and survival. While more research is needed to fully understand its potential as an anticancer agent, these findings highlight its significance as a lead compound for further development. The ability to fine-tune its structure while maintaining high enantiomeric purity will be key to unlocking its full therapeutic potential.

The safety profile of (5R,6S)-5,6-Diphenylmorpholin-2-one is another critical consideration during its development process. Comprehensive toxicological studies are necessary to assess potential side effects before moving into clinical trials. These studies often involve evaluating acute toxicity, chronic exposure effects, and potential long-term health risks associated with exposure to this compound or its derivatives. By conducting thorough safety assessments early in the development pipeline, researchers can identify any concerns before significant resources are invested in later stages.

In conclusion,(5R,6S)-5,6-Diphenylmorpholin-2-one (CAS No.282735-66-4) represents a fascinating example of how structural complexity can yield compounds with significant biological activity.(The combination of stereochemical precision, pharmacophoric features, and promising preliminary results makes it an attractive candidate for further investigation.

As research continues into this molecule, we can expect new insights into its mechanisms of action, potential therapeutic applications, and ways to optimize its properties through medicinal chemistry approaches.

The ongoing exploration of (5R,6S)-5,6-Diphenylmorpholin-2-one

holds great promise for advancing our understanding of disease processes.

Its development underscores the importance of interdisciplinary collaboration between synthetic chemists, biologists,

and clinicians in harnessing nature’s diversity for therapeutic gain.)

• 19180-79-1(5,6-Diphenylmorpholin-2-one)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)